Vir Biotechnology Surges on $240M Cash Deal and up to $1.37B Milestones
Vir Biotechnology shares hit a 52-week high after a collaboration with Astellas to advance VIR-5500 in prostate cancer, securing $240 million cash, $75 million equity and up to $1.37 billion in milestone payments. The company posted Q4 revenue of $64.1 million, a $0.31 loss and 82% PSA50 declines.
1. Strategic Collaboration with Astellas
Vir Biotechnology announced a global partnership with Astellas Pharma to advance the PSMA-targeting agent VIR-5500 in prostate cancer, securing $240 million in cash, $75 million in equity at a 50% premium, and eligibility for up to $1.37 billion in milestone payments under shared U.S. commercialization rights.
2. Fourth-Quarter Financial Results
The company reported Q4 revenue of $64.1 million, exceeding consensus of $23.2 million, and a loss of $0.31 per share versus an expected $0.41 loss, reflecting operational leverage from recent collaborations and product developments.
3. Positive Phase 1 VIR-5500 Data
In the highest dose cohort (≥3,000 µg/kg), 82% of patients achieved PSA50 declines and 53% reached PSA90, with objective responses in 45% of RECIST-evaluable patients, indicating promising anti-tumor activity and tolerability in advanced metastatic castration-resistant prostate cancer.
4. Outlook and Cash Runway
With the Astellas upfront payments and equity investment, Vir Biotechnology expects its cash, cash equivalents, and investments to fund operations into Q2 2028, while planning monotherapy and combination dose-expansion cohorts in mCRPC and mHSPC in Q2 2026 ahead of pivotal Phase 3 trials in 2027.